Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 53.16B |
| Revenue (ttm) | 29.36B |
| Net Income (ttm) | 3.45B |
| Shares Out | 3.15B |
| EPS (ttm) | 1.08 |
| PE Ratio | 15.59 |
| Forward PE | 13.14 |
| Dividend | $180.00 |
| Dividend Yield | 1,068.88% |
| Trading Day | July 26 |
| Last Price | $16.84 |
| Previous Close | $16.86 |
| Change ($) | -0.02 |
| Change (%) | -0.12% |
| Day's Open | 16.77 |
| Day's Range | 16.69 - 16.85 |
| Day's Volume | 2,129,789 |
| 52-Week Range | 14.97 - 19.53 |
XBIO stock is racing to the moon today, as Takeda Pharmaceuticals makes an announcement that will see higher demand for Xenetic products. The post XBIO Stock: Xenetic Soars on Takeda Expansion News appe...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of Moderna's COVID-19 Vaccine & booster vaccine candidate in 2022.
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from two final analyses from the Phase 3 HELP (Hereditary Angioedema Long-term...
ZURICH & BRUSSELS--(BUSINESS WIRE)--The European Federation of Crohn's and Ulcerative Colitis Associations (“EFCCA”) in collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) today announce...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2...
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co.
DUBAI, UAE, June 16, 2021 /PRNewswire/ -- Takeda Pharmaceuticals Company (TSE: 4502) (NYSE: TAK) ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, headquartered in Japan, is cele...
One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co.
DUBAI, UAE, June 9, 2021 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) has introduced the "In Their Shoes" platform, an award-winning, immersive simulation program to promote greater awareness and emp...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today at the American Transplant Congress (ATC) 2021 Virtual Connect presented results from a new subg...
Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.
Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot's efficacy waned over time but that it was still “robust” in preventing hosp...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that its dengue vaccine candidate (TAK-003) demonstrated continued ...
The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The application under priority review is seeking mariba...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) h...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under ...
Takeda Pharmaceuticals Inc. ( TAK , Financial) has cleared the decks and sees smoother sailing ahead. That's according to the Japanese company's CEO, Christophe Weber.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) ora...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponat...
Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...
Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and lower acquisition-related expenses. Takeda exceede...
Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc's COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESI...
Takeda Pharmaceutical (TAK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE)...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priori...
Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into Longview Acquisition Corp. II (NYSE:LGV.U) according to GuruFocus' Real-Time Picks, a Premium feature.
The company is taking back rights to one drug candidate and discontinuing development of another.
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide upd...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to O...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of Takeda Consumer Healthcare Comp...
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has teamed up with BridGene Biosciences to discover small molecules against hard-to-drug therapeutic targets. The deal will utilize BridGene's IMTAC Chemoproteom...
Cathie Wood's Ark Investment Management sends out an email every night listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have known to cause certain s...
Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company's...
Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd (NYSE: TAK), covering as many as six programs for genetically-defined neur...
Larry Robbins ( Trades , Portfolio )'s firm has revealed a new buy into HighCape Capital Acquisition Corp. (NASDAQ:CAPA) according to GuruFocus' Real-Time Picks, a Premium feature.
Japan's Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed an agreement with Germany-based contract manufacturer IDT Biologika GmbH to make Johnson & Johnson's (NYSE: JNJ) single-dose COVID-19 vaccine....
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood a...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufac...
OSAKA, Japan--(BUSINESS WIRE)--Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Gr...
DEPTFORD, N.J.--(BUSINESS WIRE)--BioLife Plasma Services announces the opening of its first plasma donation center in New Jersey.
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right...
OSAKA, Japan & BRISBANE, Calif.--(BUSINESS WIRE)--Takeda exercised its option to acquire Maverick, expanding its immuno-oncology portfolio with two development candidates and a T-cell engager platform
Takeda Pharmaceutical Co Ltd (NYSE: TAK) has asked regulators to approve the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (mRNA-1273 or TAK-919). Takeda filed the New Drug Application to import ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces New Drug Application submitted to import and distribute Moderna's COVID-19 vaccine candidate in Japan.
Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic en...
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 1781 |
| CEO Christophe Weber | Employees 47,099 |
| Stock Exchange NYSE | Ticker Symbol TAK |
Financial Performance
In 2020, TAK's revenue was 3.20 trillion, a decrease of -2.84% compared to the previous year's 3.29 trillion. Earnings were 376.01 billion, an increase of 749.90%.
Analyst Forecasts
According to 3 analysts, the average rating for TAK stock is "Buy." The 12-month stock price forecast is 21.78, which is an increase of 29.33% from the latest price.